1 Overview of the Regulation in the Netherlands Robert Kneepkens, MD RGA CMO Interpolis, Eureko.

Slides:



Advertisements
Similar presentations
Anna NYKIEL-MATEO Policy Officer DG COMP A3 27/11/2012
Advertisements

HIPAA Privacy Practices. Notice A copy of the current DMH Notice must be posted at each service site where persons seeking DMH services will be able to.
GENETIC INFORMATION NONDISCRIMINATION ACT Employment and Health Insurance Why GINA?
Confidentiality and HIPAA
Conference for FOOD PROTECTION Promoting Food Safety Through Collaboration.
Protecting the Privacy of Family Members in Survey and Pedigree Research Jeffrey R. Botkin, MD, MPH University of Utah.
Human Specimen Repositories: Requirements of 45 CFR part 46 PRIM&R May 5, 2004 Julie Kaneshiro DHHS Office for Human Research Protections Phone:
2010 Region II Conference Corporate Compliance Panel June 3, 2010
Ethical AND legal issues in GENETICS. objective 1- introduction. 2-major needs in study of ethics. 3-Ethical Principles in Medicine. 4-The Special Position.
© 2006 Right to Health Federal Ministry for Foreign Affairs of Austria.
Genetics: Past, Present, and Future Robert M. Fineman, M.D., Ph.D. Web siteWeb site.
Legal and Ethical Issues in Assessment Ignorance is no defense.
IRB Monthly Investigator Meeting Columbia University Medical Center IRB October 11, 2005.
Genetics and insurance in the UK
Predictive Testing & Insurance Law. Content of the Presentation: A. Predictive Tests B. Benefits of Predictive Testing C. Drawbacks of Predictive Testing.
Prescreening ä To optimize safety ä To permit the development of a sound and effective exercise prescription.
Topics Covered Abstract Headings/Subheadings Introduction/Literature Review Methods Goal Discussion Hypothesis References.
Section 24.2 Participating in Your Healthcare Slide 1 of 18 Objectives Describe how to choose and participate fully in your healthcare. Compare different.
Centre for Actuarial Research HIV/AIDS Benefits in Medical Schemes in 2002.
Workshop on Health Examination Surveys (HES) Legal and ethical issues Susanna Conti, M. Kanieff, G. Rago Istituto Superiore di Sanità (ISS) (National Public.
A Review of Board of Health Liability James A. LeNoury LeNoury Law Counsel to alPHa February 5th, 2015.
Oviedo Convention and Its Protocols – Impact on Polish Law International Bioethics Conference Oviedo Convention in Central and Eastern European Countries.
April 2011 Conducting Research at SPC Approval Process and Procedures Center of Excellence for Teaching and Learning.
LABOUR PROGRAM Occupational Health and Safety in Canada - a Shared Responsibility Presentation by: Ajit Mehat, Director General, National Labour Operations,
LOGO The collective agreement. The labour contract.
The Eighth Asian Bioethics Conference Biotechnology, Culture, and Human Values in Asia and Beyond Confidentiality and Genetic data: Ethical and Legal Rights.
LIFE INSURANCE CORPORATION OF INDIA PRESENTATION BY DR.H.C.JAIN EXE.DIRECTOR (AUDIT)
Confidentiality, Research, & Law
“What’s Ethics Got To Do With It” Presentation to the Canberra Evaluation Forum Gary Kent Head Governance Australian Institute of Health and Welfare.
Overview Context and EU Relevance Social Protection and Other Forms of Support and Assistance Employment and Necessary Pre-Conditions Using the Convention.
Special Consideration in Public Health Practice & Research Delia Wolf, MD, JD, MSCI Associate Dean, Regulatory Affairs and Regulatory Compliance Lecturer,
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Evaluating a Cultural Competency Curriculum for Disaster Preparedness and Crisis Response Guadalupe Pacheco, MSW HHS Office of Minority Health Eileen Hanrahan.
What rules apply to unregistered health practitioners? Kieran Pehm Commissioner Health Care Complaints Commission.
A European campaign on Risk Assessment Common errors in Risk Assessment.
IM NETWORK MEETING 20 TH JULY, 2010 CONSULTATION WITH 3 RD PARTIES.
FACULTY DIRECTOR TRAINING OFFICE OF EDUCATION ABROAD 1 Legal Issues and Education Abroad.
GENETIC INFORMATION NONDISCRIMINATION ACT Health Insurance Title I Employment Title II Why GINA?
Ethical AND legal issues in GENETICS. objective 1- introduction. 2-major needs in study of ethics. 3-Ethical Principles in Medicine. 4-The Special Position.
HIPAA Privacy Rule Implementation Status Report Richard M. Campanelli, J.D. Director, Office for Civil Rights Before the The Tenth National HIPAA Summit.
Human Subjects Protection Program Office of Research Compliance Navigating through the current HSPP and IRB Presented by: Danielle Griffin, M.S. Research.
1 The Public Interest Disclosure (Whistleblower Protection) Act.
PATIENT EVALUATION AND DIAGNOSIS)1) DR:TAGWA MERGHANIDNT 245.
Misc Text From choice, a world of possibilities Data Requirements: Clarifying common confusions.
HIPAA Overview Why do we need a federal rule on privacy? Privacy is a fundamental right Privacy can be defined as the ability of the individual to determine.
Principles for the Protection of Human Rights Beneficence Primary goal of health care as doing good for clients under our care. Good care requires that.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 19 – Social Policy and Employment.
Can Providers Assure Commercially Insured Adolescents Confidentiality for STI Screening and Treatment? C onflicting Laws and Innovative Approaches Abigail.
Evidence Based Disability Evaluation in the Netherlands Haije Wind, MD, PhD Research Center for Insurance Medicine Coronel Institute of Occupational.
Ethical consideration in research Before you move any further look at the ethics ……!
Health Insurance Portability and Accountability Act of 1996
THE PROBLEM Diagnosis vs. Behavior.
Genetic Testing Stephanie Fuqua Scott Hoedt Nelson Jean Ryan McMunn
FMLA Overview Amy Tucker - Bauldree.
Alignment of Part 4B with ISAE 3000
„Trade union strategies on the use of ILS in labour law reforms”
Presentation for the Equinet Seminar on Tackling discrimination and protection for carers in Europe The Greek Labor Inspectorate and its cooperation with.
Genetic testing and screening are two different things.
American Public Health Association
Dissemination Working Group Luxembourg, May 2009
A Review of Board of Health Liability
Overview of standards-related obligations and reporting by Mongolia
Human Participants Research
Freedom of movement of workers in the EU
Section 24.2 Participating in Your Healthcare Objectives
Legal Practice Amendment Bill
Office of the Vice President for Research Human Subjects Protection Program IRB Submission Process Module 4 - Health Insurance Portability and Accountability.
Institutional Review Board
Presentation transcript:

1 Overview of the Regulation in the Netherlands Robert Kneepkens, MD RGA CMO Interpolis, Eureko

2 Agenda n Medical Examinations Act (Wet op de medische keuringen, WMK). n Focus on articles 3 and 5. n Self Regulation Counsel involved parties (Zelfreguleringsoverleg betrokken partijen, ZRO). n Evaluation of the WMK. n Daily practice and comments from consultant medical officers (CMO’s). n Medical underwriting in the future.

3 Purposes of the WMK n Main purposes: n Protection of privacy and integrity of those who apply for a private life or disability insurance, or for a job. n Guarantee of the access to insurances and jobs of people with chronic medical problems. n Other intentions: n Protection of the right to informational self-determination. n Assurance that participation to population screening programmes remains at a high level, because access to private insurances is granted even after a positive genetic test.

4 Article 3: Genetic testing n No part of a medical examination may constitute a disporportionate invasion of the privacy. n Any investigation to come to the knowledge of the chance of a severe untreatable disease. n Any investigation to come to the knowledge of the presence of a severe untreatable disease, that is not yet manifest. n Restrictions in other articles or mentioned in the Second Chamber. n Article 6 of the WMK makes an exception for the HIV-test under certain conditions, and if the sum insured is above average. n The Minister of Health mentioned only two diseases currently falling under this description: Huntington’s disease and Myotonic Dystrophia.

5 Article 5: Previous genetic tests n Article 5 prohibits questions about (former investigations of) the hereditary disposition to severe untreatable diseases, … n …unless the disease is already manifest. n Article 5 also prohibits these questions if they concern family members. n Information about the hereditary disposition of the client or family members may not be used. n Article 5 is only valid if the sum insured stays below the question limit. n € 159,505 for life insurances; € 31,901 (first year) / € 21,267 (thereafter) for disability insurances. n The question limit is raised by the Minister of Health every 3 years.

6 Self Regulation Counsel (ZRO) n Article 9 of the WMK obliges the involved parties to take counsel together every three year. n The involved parties are: The Dutch Insurers Association, the Platform Insureds & Labour, the Royal Dutch Medical Association n The ZRO is responsible for a more detailed regulation: n Protocol Insurance Medical Examinations, which includes the Moratorium on Genetic Tests (meaning chromosome- and DNA-tests) and the HIV Code of Conduct n Standard health questionnaire (with a family history that is restricted to multifactorial diseases)

7 Main problems in daily practice n The evaluation of the WMK in 2006 was favourable for the insurance industry. Two important conclusions were: n The access to disability insurances in the case of self-employment remains a problem n The WMK uses unclear terms, like: manifest, hereditary, severe, untreatable. n The CMO’s feel that the WMK is outdated already. n The distinction between genetic and non-genetic is felt as unpractical and unethical, becoming more and more untenable. n Daily practice demands a simple distinction between clients that need extra protection and clients that do not.

8 Medical underwriting in the future n Further investigations or questions are allowed for (complications of) voluntary hazards and for manifest diseases. n A hazard is regarded as voluntary, if the client should know that his conduct is very hazardous for his health or longevity. n A disease can be considered being manifest, if any sign or complaint is present or has been present. The simple fact that a test - whether genetic or non-genetic – in the past proved the disease is present, is not enough.

9 Medical underwriting in the future n Extending the protection of clients with a positive hereditary disposition: n No longer just severe untreatable diseases, but all diseases with a genetic basis. n No longer just clients with ‘genetic problems’, but all clients with medical problems that are not yet manifest. n A complete ban on the use of genetic information is no longer needed. n By ending the distinction between origins of diseases, the regulations will be ready for any medical break-through in the future.